Ebola virus (EBOV) infection causes a high death toll, killing a high proportion of EBOV infected patients within 7 days. Comprehensive data on EBOV infection are very fragmented, hampering efforts in developing therapeutics and vaccines against EBOV. Under this circumstance, mathematical models become valuable resources to explore potential controlling strategies. In this paper, we employed experimental data of EBOV-infected nonhuman primates (NHPs) to construct a mathematical framework for determining windows of opportunity for treatment and vaccination. Considering a prophylactic vaccine based on recombinant vesicular stomatitis virus expressing the EBOV glycoprotein (VSV-EBOV), we found that the time window can be subject-specific, but vaccination could be protective if a subject is vaccinated during a period from one week to four months before infection. For the case of a therapeutic vaccine based on monoclonal antibodies (mAbs), a single dose might resolve the invasive EBOV replication even it was administrated as late as four days after infection. Our mathematical models can be used as building blocks for developing therapeutic and vaccine modalities as well as for evaluating public health intervention strategies in outbreaks. Future laboratory experiments will help to validate and refine the estimates of the windows of opportunity proposed here.
Introduction
with promising results for certain antivirals [4] [5] [6] , passive immunotherapy and vaccinations 7, 8 . On one hand, EBOV 14 infected nonhuman primates (NHPs) treated early with monoclonal antibodies (mAbs) were able to recover after 15 challenged with a lethal dose of EBOV 9 . Furthermore, EBOV infected human treated with mAbs in addition to 16 intensive supportive care were more likely to recover 4 . On the other hand, macaques vaccinated early with the 17 VSV-EBOV vaccine survived lethal EBOV challenge 10 . Based on VSV-EBOV vaccine, a recent community trial 18 showed protective efficacy in a ring vaccination approach 11 . These results prompted that the outcome of EBOV 19 infection is sensitive to the time of intervention. Failing to catch up with the infection course could alter the chance to 20 survive EBOV infection. Tailoring time windows of intervention is thus critical at both clinical and epidemiological 21 levels. 22 Building a tractable approach that integrates systematically biological and medical research data is crucial 23 to harness knowledge and to tailor therapies and vaccines. In this context, mathematical modeling has been a 24 useful companion approach to advance understandings on mechanisms behind incomplete empirical observations. 25 An overwhelming amount of modeling studies have been done in influenza virus [12] [13] [14] [15] [16] [17] , human papilloma virus 26 (HPV) 18 , and human immunodeficiency virus (HIV) [19] [20] [21] . These studies provided interpretations and quantitative 27 understandings of the mechanisms that control viral kinetics, which are instrumental to formulate treatment 28 recommendations [21] [22] [23] [24] [25] . Although West-Africa countries have been agitated by EBOV infection for decades, modeling 29 studies of EBOV infection are rare. To the best of our knowledge, the first endeavor to model EBOV replication in 30 vitro showed that the EBOV's basic reproductive number is at least two fold higher than that for influenza virus 26 . 31 Using in vivo experiments in NHPs, this paper aims to model the interactions between EBOV replication and 32 IgG antibody dynamics with and without passive immunotherapy. In particular, variations of simple mathematical 33 models representing different interaction mechanisms were fitted to selective parts of the experimental datasets. 34 Goodness of fit of the models were compared when needed to rule out less supportive models. Developed models 35 were then used to estimate the needed time windows to achieve effective interventions. Considering an EBOV 36 infection with a high infective dose just after vaccination, our numerical results showed that regular antibody 37 response dynamic by vaccination would rather be late to control EBOV replication. To prevent a lethal infection 38 outcome (i.e. viral load higher than 10 6 TCID 50 ), a host needs either a high antibody concentration early after 39 infection or an alternative therapy in-place sufficiently early to enable the host's adaptive immune responses to 40 catch up the infection. Simulations of the developed models provided estimates for these critical windows of 41 opportunity. In particular, therapeutic treatment could be effective if an assumed long-lived monoclonal antibody 42 was administrated up to day 4 post infection. Prophylactic vaccination can be protective if it was given at least 43 6 days before exposure. However, circulating EBOV-specific antibody could diminish below protection level 44 approximately three months after vaccination. Altogether, the framework presented here could help to tailor 45 appropriate time windows for effective therapeutic and prophylactic interventions.
46

Results
47
Study Design
48
To construct mathematical models for determining windows of opportunity for both treatment and vaccination, 49 we considered data from the two complementary strategies: a passive 9 and an active immunization intervention 50 protocol 10 . Schematic representation of the NHP experiments are provided in Fig. 1 . Additional experimental 51 details can be found in Materials and Methods. Viral load data in the controlled and treated cases were extracted 52 from both the studies 9, 10 . Antibody dynamics (IgG) data were available to assess its effects on the viral load 10 53 whereas effects of mAbs were only available in terms of administrated time points and dosages.
54
Note that NHPs data is considered the best animal model to recapitulate EVD observed in humans 27 . In addition, 55 controlled and defined experimental conditions are key guidances to model the complex interactions between virus 56 and immune responses, e.g., defined time of infection and innoculum, consistent sampling time among the subjects, 57 uniform host's conditions, and consequently immune responses. The viral load was considered to determine the 58 effect of intervention strategies. Epidemiological and pharmacological studies reported that a viral load higher than 59 10 6 copies/mL 4, 28 is associated to a higher mortality rate, whereas observations on experimental data in NHPs 60 showed animals with viral load levels higher than 10 6 TCID 50 were fatal 9, 10 . Thus, we assumed that subjects with 61 viral load levels higher than this threshold will have a severe outcome. 
Antibody profile after EBOV vaccination 63
To avoid ending up with a complex interaction model, IgG data were modeled independently to have a general profile of IgG responses, which is used later as an input in models of viral replication. This was done by using the IgG dynamics data after EBOV vaccination but before EBOV infection challenge 10 . A typical immunogen dynamic can be summarized in two phases: a catabolic decay phase during which the antigen is taken up by macrophages and other phagocytic cells, and an immune elimination phase during which newly synthesized antibodies combine with the antigen forming antigen-antibody (AgAb) complexes which are also phagocytosed. These dynamics can be written as follows
where δ Ag denotes the antigen removing rate. The parameter β Ag denotes the rate of AgAb complexes forming.
The processed immunogen is then delivered to lymph nodes as the stimulus sources of the B-cell activation. This process can be written as an auxiliary delay state
in which the processed immunogen is converted to the signal G Ag in time τ Ag . The above two processes lead to B-cell activation, proliferation, and antibodies secretion which can be summarized as follows
where r Ab reflects the end result of the three processes. The parameter δ Ab is the decaying rate of IgG which is 64 approximately 28 days 29 . The parameter β Ab denotes the rate of AgAb complex forming. An ineffective antigen 65
will not able to induce B-cell activation, i.e. r Ab = 0. Applying this to the IgG kinetic data 10 results in a classical 66 antibody response picture, namely a lag phase follows by an exponential phase before reaching a plateau ( Fig. 2A ). 67
A high and steady level of IgG can only be acquired after two weeks. As a result, antibody responses may offer 68 negligible protection during the first week after vaccination.
69
EBOV replication profile 70 EBOV replication dynamics in the absence of any interventions were also modeled separately. This was done using EBOV titers (in TCID 50 ) of only the control cases in the used datasets 9, 10 . We considered two models, including the logistic growth model and a modified logistic growth model as follows
Lag-Logistic :
where r V denotes the virus replication rate and K V denotes the carrying capacity of the host. The parameter I n (B) Viral titers in control cases form both data sources 9, 10 were used to evaluate EBOV replication models in treatment-free scenarios. The follow-up data were stopped when the animals reached the endpoints to be euthanized 9, 10 . Table S3 ). EBOV needed approximately three days to gain the momentum before growing exponentially, suggesting 76 there is a crucial period for a successful treatment.
77
This result, in agreement with experimental observations, shows that even if the host develops a normal antibody 78 response, EBOV would replicate unrestrained by the antibodies during the first week. As innate immune responses 79 and consequently cellular adaptive responses were highly disrupted by EBOV 3 , this points towards the central role 80
of antibodies in survivors of EBOV infection. Noting that the EBOV replication profile represents the cases infecting 81 with a lethal dose, as such a varied, subject-specific lag-phase as a function of the innoculum can be expected. 82
Nevertheless, in terms of safety, using EBOV dynamics based on a lethal dose to evaluate treatment therapies will 83 provide the most conservative predictions.
84
Tailoring windows of opportunity for prophylactic vaccines (VSV-EBOV) 85 To account for the effect of antibodies in controlling the virus, the viral replication model Eq. (5) was modified to
To connect to EBOV dynamics in (5), the parameter K Ab was introduced reflecting a functional threshold at which 86 the antibody titers inhibit EBOV net growth rate. Crossing this threshold leads to the virus titer being cleared. To 87 evaluate this model, IgG titer and viral load data of two animals vaccinated three days before EBOV infection were 88 used (M31 and M32); these were the only two animals with detectable viral titers in the experiment 10 . Firstly, the 89 antibody dynamics Ab were obtained by fitting the equations Eq. (1)-(3) to the IgG data of the two subjects. The 90 parameters δ Ab , δ Ag , β Ag , and β Ab were fixed to the estimates derived earlier from the data of all subjects ( Fig. 2A ). 91
The two parameters τ Ag and r Ab were refitted to allow subject-specific responses, see Table S2 . Afterwards, the Ab 92 outputs from the first step were used as inputs to fit the model Eq. (6) to viral titers data of the two subjects. With 93
the assumption that EBOV would replicate indifferently among infected subjects, the parameters K V and I n were 94
fixed to the previous estimates from the model Eq. (5).
95 Figure 3A -C shows that the models Eqs. (1) to (3) rendered faithfully the IgG dynamics in the three animals. 96
Differences observed in the dynamics can be explained by subject-specific responding time to stimulate B cells (τ Ag ) 97
and to produce EBOV specific antibodies (r Ab ), see Table S2 . Figure 3D -E show that the model Eq. (6) reproduced 98 the viral dynamics in the two subjects (M31 and M32). The differences in IgG dynamics also lead to different 99 working threshold estimates of K Ab for each subject, reflecting possibly different antibody responses strength.
100
The model of the interactions between IgG and EBOV allow to simulate windows of opportunity for vaccination. 101
By varying the time of vaccination, a time period during which a vaccine administration could prevent a likely-lethal 102 viral load level can be estimated. Since the threshold for a functional antibody response (K Ab ) can be subject-specific 103 (Fig. 3F ), a range of thresholds based on the observed IgG data from 10 2.5 to 10 4.5 were tested. Based on data of the 104 control cases ( Fig. 2B ) and empirical observations in EBOV-infected human 28 , a subject expresses viral load level 105 higher than 10 6 could be considered as having a severe outcome. Figure 4 illustrates the time windows for different 106 vaccination time and different working threshold K Ab . Noting while the chosen level can be subjective, one can 107 simply lower the values to have a more conservative time window estimate.
108
It can be observed that the higher the working thresholds of antibody the shorter the time windows of inter-109 vention. For each K Ab threshold, there is a safe time window where viral titers were not observed. For example, a 110 threshold K Ab = 10 4 could prevent EBOV replication from reaching severe viral load levels if only the subject had 111 been vaccinated at least 6 days before infection. However, if the subject had received vaccination for more than four 112 months before, circulating antibody levels could have decreased below the working threshold (K Ab ) at the time of 113
infection. As such, if the secondary antibody responses to EBOV infection are not considerably faster than primary 114 responses, the subject would also succumb to the disease. Here, the secondary antibody response to EBOV was 115 assumed similar to a primary response, i.e. similar to the dynamic observed in Fig. 2A , and that the IgG titer were 116 accumulative to primary response.
117
Remarkably, assuming an infected subject would develop the same IgG profile as a vaccinated subject, simulation 118 results showed that a normal IgG response will fail to keep the viral load from reaching its peak, regardless of the 119 working threshold K Ab (Fig. S1) . At best, a normal IgG profile developing from the day of infection could clear the 120 were negligible, the viral dynamics are rewritten as follows
where M is the administrated dose of mAbs (see Materials and Methods) and h is the ODE integration step size. 123
Here the mAbs are assumed acting indifferently from IgG antibody, i.e. not only reducing the viral replication 124 but also promoting the viral clearance. The Eq. (3) expressed the assumptions that the mAbs concentration was 125 accumulative over doses and decayed exponentially during the infection course. As a result, the combination of 126 parameter K m and the dynamics of the mAbs leads to similar working threshold mechanism as in Eq. (6) . Here, the 127 parameter K m represents the maximum effect of the mAbs.
128
Evaluation of the model Eqs. (7) to (8) were done by fitting to the viral dynamics data, separately for each treated 129 animal with observable viral load 9 . As the model is ignoring the effects of antibody responses, only viral load data 130 at time points from day 0 to day 9 were used. The parameters r V , K V , and I n were fixed to the earlier estimates in 131
Eq. (5) . For simplicity, the mAbs are assumed to have a stable and long elimination half-life of 28 days across the 132 subjects 30 .
133 Figure 5 shows that the model portrays adequately the viral load kinetics in every subjects. Interestingly, the 134 mAbs treatment effect seemed to be separated in two groups: a low effect group (K m < 1) that allowed viral titers to 135 linger until day 9 and a high effect group (K m > 1) that quickly stemmed down the viral titers (details in Table S3 ). 136
Extrapolating the model Eq. (7) to time points after day 9 post infection showed a sustained viral load in those 137 subjects whose mAbs effect is low (K m < 1), see Fig. 5 . Because the mAbs was already assumed having the longest 138 elimination half-life observed in natural antibody, this result suggests that mAbs treatment alone may be insufficient 139 for those the mAbs effect is low.
140
To take into account the effect of host's IgG response, we incorporated the general IgG profile developed earlier into the model Eq. (7) and simulated the viral load dynamics with a conservative working threshold 10 4.5 in each subject as follows
Here it was continued to assume that EBOV-infected subjects would able to develop a similar IgG profile as in those 141 subjects vaccinated with VSV-EBOV 10 . Figure 5 shows that including the effects of IgG into the treatment model 142 replicated closely the viral load data. Therefore, the host's antibody response (IgG) would have played the key role 143 in resolving the infection for those mAbs treatment were not sufficient.
144
In light of these results, therapeutic treatment windows can also be developed using the model Eq. (8) and 145
Eq. (9) . For illustration purpose, we varied the time of treatment administration to define which treatment initiation 146
can prevent viral load to reach fatal levels, i.e., viral load is higher than 10 6 TCID 50 . Figure 6 illustrates EBOV 147 kinetics considering a single dose treatment approach, we can observe that a single dose of a long-lived mAbs 148 administrated up to day 4 post infection was able to clear the virus before it reached the likely-lethal viral load. 
Discussion
150
The recent unprecedented EBOV outbreak in West Africa has affected more people than in all previously outbreaks 151 combined. While significant progress has been made in therapeutics and vaccines against EBOV on preclinical level, 152 no licensed products are currently available. Lack of market for products, consequently interests of pharmaceuticals 153 companies could have hindered the progress. Furthermore, the high pathogenicity of EBOV hampers the possibil-154
ities to have comprehensive data and to conduct clinical and efficacy studies in EBOV infection. In this context, 155
using mathematical models in combination with experimental data can be essential for EBOV countermeasure 156 development.
( Fig. 2A) , the pace of antibodies response would still be too slow to counteract EBOV replication, which needs only 159 three days to start an exponential growth (Fig. 2B) . In fact, antibody titers were negligible during the first week post 160 vaccination. Therefore, protection to EBOV infection depends on having a high level of antibodies as all animals 161 vaccinated sufficiently early were survived 10 . Future experiments should closely monitor IgG dynamics in infected 162 versus vaccinated cases. Comparing the responding time in the two situations will help to clarify if the adaptive 163 immune responses are indeed malfunction. hour can also produce the viral load data (Fig. S2 ) but the estimated drug effect were rescaled (Table S3 ). However, 183 this can be easily overcome when common pharmacokinetics parameters are available, such as the elimination 184
half-life for the mAbs. This approach opens the opportunity to mathematically evaluate EBOV treatment regimens. 185
Our example of assessing a one-dose regimen illustrates that highly beneficial information can be obtained.
186
Note that the windows of opportunity reported here based on data of NHPs infected with a lethal infective 187 dose, thus it would represent the infection in fatal cases. Depending on the infective dose and individual responses 188 strength (K Ab ) in each situation, the windows will become wider or narrower. Varying these conditions and 189 simulating the viral load showed that the validity of the models were supported when the generated viral load 190 dynamics exhibits known characteristics of EBOV infection in human (Fig. 7) . The red area depicts the total viral load (AUC) that is used at the reference threshold for lethal criteria. This equals to the total viral load in control cases presented in Fig. 2 . Subjects withstand a total viral load higher than the threshold is assumed fatal, otherwise they will recover once the viral load is resolved under detection level.
until the exponential growth of EBOV ranges from 2.6 to 12.4 days (median: 3.8), which is equivalent to the 192 incubation period of EBOV in human 1 . Additionally, the time from from infection to death ranges from 8.1 to 15.1 193 days (median: 9), and the time to recovery ranges from 6.9 to 17.6 days (median: 9.7) also resemble to that observed 194 in practice 1 . Based on these kinetics, infected subjects could develop the disease after several days having no 195 detectable viral load. This suggests that EBOV treatments need to provide as early as possible for all those exposed, 196 even that they express no signs or symptoms. Cares and quarantine procedures would also need to be provided for 197 exposed individuals at least twenty days which is twice the maximum incubation period estimated above.
198
In summary, this paper proposed mathematical models by using selective parts of different data sources for 199 model evaluation, resulting in a general framework for the development of treatment regimens and vaccination 200 strategies. On top of that, public health policies and initiatives can also be evaluated with realistic treatment efficacy 201
and subject-specific immune responses. In the scarcity of data, mathematically modeling approaches posits a strong 202 potential to uncover useful information in controlling infectious diseases which is gradually become pivotal in the 203 years to come.
204
Materials and Methods
205
Experimental data 206 Experimental data considering a therapeutic vaccine using monoclonal antibodies (mAbs) was taken from 9 . The 207 mAbs were engineered to specifically recognize the EBOV glycoprotein (GP) inserted in the membrane of the 208 viral particle. In this experiment, a group of 12 macaques were administrated mAbs intravenously at day 3, 6, 9 209 post infection with a constant dose of with 50mg/kg. These were divided into two groups, 6 NHPs received the 210 monoclonal antibodies combination ZMapp1 (Group A) and the other 6 received ZMapp2 (Group B) 9 . No treatment 211 was given to the two control cases. EBOV titer increased rapidly but ceased when the first dose of mAbs was 212 administrated. The viral load continued to increase in the control cases until the subjects were euthanized at day 7 213 post infection. All animals cleared the virus from day 10 onward, with the exception of A1 which presented a high 214 clinical score.
215
Experimental data for a prophylactic vaccine based on recombinant vesicular stomatitis virus expressing the 216 EBOV GP (VSV-EBOV) was taken from 10 . In this experiment, groups of two or three macaques were vaccinated at 3, 217 7, 14, 21, and 28 days before EBOV challenge. Macaques were immunized with a single intramuscular injection of 218 plaque-forming units (PFU) of VSV-EBOV. An ineffective vaccine (the VSV-Marburg virus vaccine (VSV-MARV)) 219 was given to three control cases. IgG titers were measured regularly four weeks before and after the challenge. All 220 the vaccinated animals showed a sharp increase of IgG titers one week after vaccination. IgG titers sustained at 221 the level above up to two months. EBOV titers were monitored up to 9 days after the challenge. All the control 222 cases showed a high level of viral titers and were euthanized five to seven days after infection. Viral titer was not 223 observed in all the animals vaccinated at least seven days before the challenge. Among three animals vaccinated 224 three days before the challenge, two had observable viral load in which one died and the other survived. A 225 schematic representation of both NHPs experiments is provided in Fig. 1 . load were imputed as 10 0.15 TCID 50 32 . Model fitting was conducted in log ten for both the states and parameters. 232
Objective function was defined as the root mean square error of the fitted value and the experimental data. 233
Optimization was done with the Differential Evolution algorithm using the recommended configurations 33 . All 234 simulations were done using R 34 . Details of model fitting can be found in Table S1 .
